NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
JARDIANCE (empagliflozin) by Boehringer Ingelheim is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2014.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JARDIANCE (empagliflozin) is a once-daily oral small-molecule SGLT2 inhibitor approved for type 2 diabetes management. It works by blocking sodium-glucose cotransporter 2 in the kidney, increasing glucose excretion via urine and lowering blood glucose independently of insulin. The drug has expanded beyond glycemic control to cardiovascular and renal protective indications in diabetic patients.
$8.8BPart D
PeakStable
8.2 years to LOEJARDIANCE maintains peak commercial performance with $8.8B in annual Part D spending, indicating large, mature brand teams focused on market penetration and patient retention strategies.
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
Started Jan 2028
3,000 enrolled
Heart FailurePreserved Ejection Fraction
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Started Jan 2028
5,000 enrolled
Heart Failure of Reduced Ejection Fraction (HFrEF)
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Started Aug 2026
34 enrolled
Chronic Kidney Diseases
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Started May 2026
410 enrolled
Congenital Heart Disease
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Started Mar 2026
200 enrolled
Diabete Type 2
Worked on JARDIANCE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.